Patent · US Active

Prevention of adverse effects caused by CD3 specific binding domains

US11633408B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

Gerhard Zugmaier · Munich, DE
Dirk Nagorsen · Munich, DE
Juergen Scheele · Munich, DE

Key dates

Filing date	Oct 11, 2018
Grant date	Apr 25, 2023
Priority date	—
Expiry date	Oct 11, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.